ARTICLE | Clinical News
XOMA 358: Ph II data
March 17, 2017 1:05 PM UTC
Data from 13 patients ages 42-68 with hypoglycemia post-bariatric surgery in an open-label, U.S. Phase II trial showed that single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. ...
BCIQ Company Profiles
BCIQ Target Profiles